Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer

Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer

Background: Approximately 30 % non-small cell lung cancer (NSCLC) patients carry KRAS mutations in western countries. First-line chemotherapy combined with immunotherapy has been the standard therapeutic regimen for KRAS-mutant NSCLC patients. This population could also benefit from chemotherapy com...

Full description

Saved in:
Bibliographic Details
Main Authors: Huiping Qiang, Yue Wang, Yao Zhang, Jingwen Li, Lincheng Zhang, Huawei Du, Xuxinyi Ling, Shuhui Cao, Yan Zhou, Runbo Zhong, Hua Zhong
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Translational Oncology
Subjects:
Non-small cell lung cancer
KRAS mutation
Immune checkpoint inhibitor
TP53
PD-L1
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523325000488
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items